Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBA Part 2 oral salbutamol in cystic fibrosis with residual CFTR function
NL-OMON24538Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of salbutamol in cystic fibrosis (CF), sponsored by University Medical Center Utrecht. Primary endpoints: Pulmonary function and Airway resistance. Started Sep 2015; status: active, not recruiting.
02
Drugs
salbutamol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON24538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24538.